These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 23522958)

  • 1. Mouse models for studying angiogenesis and lymphangiogenesis in cancer.
    Eklund L; Bry M; Alitalo K
    Mol Oncol; 2013 Apr; 7(2):259-82. PubMed ID: 23522958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
    Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
    García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
    J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy.
    Stacker SA; Achen MG
    Lymphat Res Biol; 2008; 6(3-4):165-72. PubMed ID: 19093789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
    Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
    Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis.
    Cao R; Ji H; Feng N; Zhang Y; Yang X; Andersson P; Sun Y; Tritsaris K; Hansen AJ; Dissing S; Cao Y
    Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15894-9. PubMed ID: 22967508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
    Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
    Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallels of Resistance between Angiogenesis and Lymphangiogenesis Inhibition in Cancer Therapy.
    Jones D
    Cells; 2020 Mar; 9(3):. PubMed ID: 32244922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
    Shibuya M
    BMB Rep; 2008 Apr; 41(4):278-86. PubMed ID: 18452647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
    Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
    Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical imaging and tumor angiogenesis.
    Lin PC
    J Cell Biochem; 2003 Oct; 90(3):484-91. PubMed ID: 14523982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
    Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
    BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.